M&T Bank Corp Sells 56,186 Shares of West Pharmaceutical Services, Inc. $WST

M&T Bank Corp decreased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 72.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,814 shares of the medical instruments supplier’s stock after selling 56,186 shares during the quarter. M&T Bank Corp’s holdings in West Pharmaceutical Services were worth $4,772,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Zions Bancorporation National Association UT bought a new stake in West Pharmaceutical Services in the 1st quarter valued at $25,000. Quarry LP bought a new stake in shares of West Pharmaceutical Services in the first quarter worth about $27,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of West Pharmaceutical Services by 193.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 95 shares in the last quarter. CVA Family Office LLC lifted its position in shares of West Pharmaceutical Services by 573.3% in the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after buying an additional 172 shares in the last quarter. Finally, Cromwell Holdings LLC grew its holdings in West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after buying an additional 188 shares in the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 1.0%

WST stock opened at $281.42 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $187.43 and a twelve month high of $348.90. The stock has a market capitalization of $20.24 billion, a price-to-earnings ratio of 41.69, a price-to-earnings-growth ratio of 4.39 and a beta of 1.17. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $273.34 and its two-hundred day simple moving average is $247.37.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million during the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

WST has been the topic of several recent research reports. Rothschild & Co Redburn initiated coverage on West Pharmaceutical Services in a report on Monday, September 15th. They set a “buy” rating and a $311.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $345.00 price target on shares of West Pharmaceutical Services and gave the company a “buy” rating in a research note on Friday, October 24th. Barclays increased their price objective on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research report on Monday, October 27th. Cowen began coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating on the stock. Finally, Evercore ISI upped their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus target price of $343.36.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.